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compared to best supportive care alone in patients with refractory or 
recurrent disease within 6 months of initial platinum therapy.
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Background: This study was designed to evaluate the predictive role 
of mRNA quantiﬁcation of three genes potentially related to platinum/
etoposide therapy in small-cell lung cancer (SCLC): ERCC1, RRM1 
and TOPOIIα.
Methods: A retrospective analysis was therefore performed on 103 
consecutive patients with either limited stage (LS) or extensive stage 
(ES) SCLC. Total RNA was extracted from microdissected sections of 
103 formalin-ﬁxed, parafﬁn embedded pre-treatment biopsies of SCLC 
patients. Relative quantiﬁcation for ERCC1, RRM1 and TOPOIIα plus 
an internal reference gene (b-actin) was done by Real Time PCR using 
intron-spanning primers. ERCC1 was evaluated also by immunohisto-
chemistry (IHC) with a semi-quantitative score. 
Results: Eighty-ﬁve samples (83%) were successfully ampliﬁed by 
Real Time PCR and a gene expression level was detectable in all 
samples. Out of these 85 cases, 45 (53%) had LS SCLC and 40 (47%) 
ES SCLC; overall response rate (RR) to chemotherapy was 65% (56 
cases), median survival was 9.9 months. 
IHC staining of ERCC1 was positive in 2 out of 85 patients with no 
correlation with clinico-pathological factors. A signiﬁcant correla-
tion emerged between ERCC1 and RRM1 mRNA levels (Rs=0.34, 
p=0.001). 
Low TOPOIIα expression was associated to increased RR in LS 
patients (p=0.025) and TOPOIIα levels were lower in patients who had 
a complete response than in patients with either partial responses or no 
response (p=0.01). At univariate analysis LS patients with low ERCC1 
mRNA levels had longer median survival (14.9 months vs. 9.9 months, 
p=0.01), while RRM1 and TOPOIIα levels showed no signiﬁcant inﬂu-
ence on survival. At multivariate analysis, ERCC1 was conﬁrmed as 
an independent prognostic factors for survival in LS patients, together 
with performance status (PS) and response to chemotherapy. No signiﬁ-
cant prognostic role was found for ERCC1, RRM1 and TOPOIIα in 
patients with ES SCLC. 
Conclusions: Pharmacogenomics have been widely studied in ad-
vanced NSCLC, while poor efforts have so far been devoted on such 
topic in SCLC. ERCC1 and TOPOIIα mRNA levels could represent 
new reliable markers to predict response to treatment and clinical out-
come in subgroups of SCLC patients. The path to the individualization 
of therapy through selection of patients based on pharmacogenomic 
data should be pursued to improve prognosis of SCLC. 
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HGF/c-Met axis modulate Topoisomerase-I activity and cell 
viability in small cell lung cancer
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Small cell lung cancer (SCLC) is a very aggressive malignancy, which 
metastasizes very early in its course. Current therapies have apparently 
reached their maximum efﬁcacy, prompting the search for new thera-
pies and the combination of new therapies with current treatment. Pre-
viously we identiﬁed the c-Met receptor tyrosine kinase to be expressed 
and functional in SCLC. We have shown that hepatocyte growth factor 
(HGF), the ligand for c-Met causes tyrosine phosphorylation of c-Met 
on the pY1230/1234/1235 autophosphorylation site, in addition to ac-
tivation of important downstream signaling intermediates, such as Akt 
and ERK 1/2. There was also strong correlation between phosphor-Met 
and with Topoisomerase I. Utilizing the novel c-Met tyrosine kinase 
inhibitor, SU11274, we have shown that this HGF mediated signaling 
can be abrogated in a dose-dependent fashion. Since Topoisomerase 
I inhibition is a relatively effective approach for treating SCLC, we 
determined whether Topoisomerase I inhibition (using the Irinotecan 
metabolite SN38) would be synergistic when combined with the novel 
c-Met inhibitor, SU11274, to reduce cell viability in SCLC cell lines. 
Synergism was evident in both of the SCLC cell lines (H69 and H345) 
used for the study, but was enhanced in the H69 cell line. This was 
apparently due to the R988C mutation in the c-Met juxtamembrane do-
main. We also show that the HGF/c-Met axis can modulate Topoisom-
erase I activity and this modulation can be abrogated by SU11274. This 
combination of SU11274 and Topoisomerase I inhibitor could provide 
an efﬁcacious combination for the treatment of SCLC. 
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Gene therapy represents a novel treatment strategy for small cell lung 
cancer (SCLC), which is a highly aggressive malignancy characterized 
by poor prognosis. Due to the metastatic nature of SCLC, treatment 
must be performed systemically requiring a high level of targeting. At 
this laboratory transcriptionally targeted gene therapy has been devel-
oped utilizing promoters identiﬁed as highly and speciﬁcally active in 
SCLC. In addition a promising nonviral gene delivery system is being 
tested and optimized in vivo. 
In general only few therapeutic genes have been tested for SCLC gene 
therapy. The aim of the present project is to test various therapeutic 
genes with very different mechanism of action, and compare their ef-
ﬁcacy in vitro. The genes were cloned to be regulated from the SCLC 
speciﬁc promoter, INSM1, tested by transient transfections into SCLC 
cell lines and cell survival evaluated with MTT assay. 
